Creative Planning
NAUT icon

Creative Planning’s Nautilus Biotechnolgy NAUT Stock Holding History

Creative Planning’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-17,444
Closed -$240K – 2402
2021
Q1 		$240K Buy
+17,444
New +$242K ﹤0.01% 1953

Other funds holding NAUT

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MVG
Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $4.42B AUM 22.6% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Creative Planning's NAUT Position: Q2 2021 in Review

Creative Planning sold out of Nautilus Biotechnolgy (NAUT) in Q2 2021, closing a stake of 17,444 shares — an estimated $240K sold.

Creative Planning first reported a position in NAUT in Q1 2021 and held it in 1 quarter. The position peaked at $240K in Q1 2021. 56 funds tracked by Wall St. Rank hold NAUT as of Q2 2021.

  • Creative Planning reported no remaining Nautilus Biotechnolgy position as of Q2 2021 after selling out during the quarter.
  • Creative Planning sold 17,444 Nautilus Biotechnolgy shares in Q2 2021, an estimated $240K.
  • Creative Planning first reported a position in Nautilus Biotechnolgy in Q1 2021 and held it in 1 quarter.
  • Creative Planning's Nautilus Biotechnolgy position peaked at $240K in Q1 2021.
  • 56 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q2 2021.

Based on Creative Planning's 13F filing for Q2 2021, filed 4 Aug 2021.